These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8263501)

  • 1. Sensitive assays for hepatitis A antibodies.
    Miller WJ; Clark W; Hurni W; Kuter B; Schofield T; Nalin D
    J Med Virol; 1993 Nov; 41(3):201-4. PubMed ID: 8263501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of antibodies to the nonstructural 3C proteinase of hepatitis A virus.
    Stewart DR; Morris TS; Purcell RH; Emerson SU
    J Infect Dis; 1997 Sep; 176(3):593-601. PubMed ID: 9291304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M.
    Hess G; Faatz E; Melchior W; Bayer H
    J Virol Methods; 1995 Feb; 51(2-3):221-8. PubMed ID: 7738142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine.
    Laufer DS; Hurni W; Watson B; Miller W; Ryan J; Nalin D; Brown L
    Clin Infect Dis; 1995 Apr; 20(4):868-71. PubMed ID: 7795087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in a phase IV study.
    Ye C; Luo J; Wang X; Xi J; Pan Y; Chen J; Yang X; Li G; Sun Q; Yang J
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2165-2170. PubMed ID: 28631170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.
    Newcomer W; Rivin B; Reid R; Moulton LH; Wolff M; Croll J; Johnson C; Brown L; Nalin D; Santosham M
    Pediatr Infect Dis J; 1994 Jul; 13(7):640-2. PubMed ID: 7970954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization.
    Zaaijer HL; Leentvaar-Kuijpers A; Rotman H; Lelie PN
    J Med Virol; 1993 May; 40(1):22-7. PubMed ID: 8515245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G; Gizaris V; Papaevangelou G
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
    Maiwald H; Jilg W; Bock HL; Löscher T; Sonnenburg F
    Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.
    Midthun K; Ellerbeck E; Gershman K; Calandra G; Krah D; McCaughtry M; Nalin D; Provost P
    J Infect Dis; 1991 Apr; 163(4):735-9. PubMed ID: 1849160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host immune response to hepatitis A virus.
    Stapleton JT
    J Infect Dis; 1995 Mar; 171 Suppl 1():S9-14. PubMed ID: 7876654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response.
    Delem AD
    Biologicals; 1992 Dec; 20(4):289-91. PubMed ID: 1339039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.
    Chen XQ; Bülbül M; de Gast GC; van Loon AM; Nalin DR; van Hattum J
    J Hepatol; 1997 Feb; 26(2):260-4. PubMed ID: 9059944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children.
    Castillo de Febres O; Chacon de Petrola M; Casanova de Escalona L; Naveda O; Naveda M; Estopinan M; Bordones G; Zambrano B; Garcia A; Dumas R
    Vaccine; 1999 Nov; 18(7-8):656-64. PubMed ID: 10547425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccination against hepatitis A].
    Zamir D; Zamir H; Weiner P
    Harefuah; 1998 Aug; 135(3-4):114-8. PubMed ID: 9885656
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis A-vaccines: a comparison between three methods of antigen determination.
    Burkhardt F; Glück R; Finkel-Jimenez B; Brantschen S
    Dev Biol Stand; 1996; 86():129-35. PubMed ID: 8785942
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A].
    Borcić B; Kovac S; Mihaljević I; Dobrovsak-Sourek V; Ljubicić M
    Lijec Vjesn; 1996; 118(7-8):162-4. PubMed ID: 8965633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on re-immunization with live attenuated hepatitis A vaccine].
    Liu Y; Xu Z; Ouyang P
    Zhonghua Yu Fang Yi Xue Za Zhi; 1998 May; 32(3):162-4. PubMed ID: 10322791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children.
    Balcarek KB; Bagley MR; Pass RF; Schiff ER; Krause DS
    J Infect Dis; 1995 Mar; 171 Suppl 1():S70-2. PubMed ID: 7876652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.